Unknown Manufacturer
Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.
Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
2 associated conditions
